Discriminatory Precision of Neutrophil Gelatinase-Associated Lipocalin in Detection of Urinary Tract Infection in Children: a Systematic Review and Meta-Analysis

Arash Abbasi¹,², Fardin Nabizadeh³, Maryam Gardeh³, Kosar Mohamed Ali⁴, Mahmoud Yousefifard⁵*, Mostafa Hosseini¹,⁶†

¹. Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
². Department of Pediatrics, Division of Nephrology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
³. Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.
⁴. College of Medicine, University of Sulaimani, Sulaimani, Iraq.
⁵. Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
⁶. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Received: February 2020; Accepted: March 2020; Published online: 25 April 2020

Abstract: Introduction: There is a significant discrepancy between studies on diagnostic precision of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis of urinary tract infection (UTI). Therefore, the present systematic review and meta-analysis was designed to assess the diagnostic value of NGAL in diagnosis of UTI in children and adolescents. Methods: An extensive search was performed on Medline, Embase, Scopus and Web of Science databases by the end of 2019. Two independent researchers screened and summarized the data. Discriminatory precision of urinary and serum NGAL was assessed by reporting area under the curve, sensitivity, specificity and diagnostic odds ratio with 95% confidence interval (95% CI). Results: Data from 12 studies were included. The area under the curve of urinary and serum NGAL for diagnosis of UTI in children and adolescents at the best cut-off point (between 30-39.9 ng/ml) was 0.95 (95% CI: 0.93 to 0.97) and 0.83 (95% CI: 0.80 to 0.86), respectively. Sensitivity, specificity and diagnostic odds ratio on urinary NGAL at these cut-off points were 0.89 (95% CI: 0.64 to 0.97), 0.89 (95% CI: 0.71 to 0.97) and 67 (95% CI: 5 to 891), respectively. Sensitivity, specificity and diagnostic odds ratio of serum NGAL in UTI detection were 0.85 (95% CI: 0.70 to 0.90), 0.81 (95% CI: 0.69 to 0.88) and 9.53 (95% CI: 1.52 to 59.65), respectively. Conclusion: The present meta-analysis showed that urinary NGAL had a high diagnostic value in detection of UTI in children and adolescents with an optimum cut-off point in the range of 30-39.9 ng/ml.

Keywords: Lipocalin-2; Urinary Tract Infections; Child; Predictive Value of Tests

1. Introduction

Urinary tract infection (UTI) is one of the most common childhood diseases, with a prevalence rate of 30% (1, 2). Data presented in 2007 showed that there were 10.5 million visits due to UTI (3), most of which occurred within one year after the first episode of UTI (4). This disease leads to serious complications such as renal scar, renal failure and hypertension (5, 6). Although UTI is a common condition among children, the nonspecific symptoms of UTI in this age group makes urine culture the sole reliable diagnostic test. How-

*Corresponding Author: Mahmoud Yousefifard, Assistant Professor of Physiology, Physiology Research Center, Hemmat highway, Tehran, Iran. E-mail: yousefifard.m@iums.ac.ir
†Corresponding Author: Mostafa Hosseini, Department of Epidemiology and Biostatistics School of Public Health, Tehran University of Medical Sciences, Poursina Ave, Tehran, Iran; Email: mhosseini110@yahoo.com
ever, the high chance of contamination of the sample and the relatively long waiting time for the results of the culture test, may postpone the diagnosis of UTI in children. Some studies suggest that a combination of ultrasound, scintigraphy, and voiding cystography could improve the diagnosis of UTI (7, 8). However, even these imaging techniques do not have an acceptable diagnostic value in detecting UTI. In the meantime, use of urinary biomarkers may be helpful in diagnosis of UTI. Neutrophil gelatinase-associated lipocalin (NGAL) has been introduced as a diagnostic biomarker for kidney disease in numerous studies. For example, in two previous meta-analyses, we found that serum/urinary concentration of NGAL has an acceptable value in diagnosis of acute kidney injury (9, 10). There are also other studies that have evaluated the value of NGAL in identifying UTI. For example, Valdimarsson et al. in 2017 showed that urinary NGAL has a sensitivity and specificity of 96 to 100% in diagnosis of UTI (11). Similar findings have been reported by Lee et al. (12). But Kitao et al. suggested that urinary NGAL level in patients with UTI has low precision in predicting patient outcomes (13). This disagreement led us to design the present systematic review and meta-analysis to determine the diagnostic value of NGAL in detection of UTI in children and adolescents.

2. Methods

2.1. Study design

The Meta-analysis of observational studies in epidemiology (MOOSE) guideline was used to summarize the evidence on value of NGAL in diagnosis of UTI in children and adolescents (14). We used a similar method with our previous published works to conduct the present meta-analysis (15-20).

2.2. Eligibility criteria

In this systematic review and meta-analysis, all observational studies aimed at investigating the value of NGAL in detection of UTI in children and adolescents were included. Exclusion criteria were studies without a UTI group, duplicate articles, recurrent UTI, in vitro/animal studies, adult studies, and reviews. PICO in the present study was defined as follows. Problem or study population (P): children with UTI; index test (I): urine and serum levels of NGAL; comparison (C): with non-UTI subjects; outcome (O): The desired outcome was the diagnostic value of NGAL in diagnosis of UTI.

2.3. Search strategy

The databases searched for in the present study included Medline through the PubMed, Embase, Scopus and ISI Web of Science. This study examined all indexed studies from the establishment of the database to the end of 2019. In addition, we performed manual searches on Google search engine, Google Scholar and bibliography of related articles. Keywords associated with UTI in combination with words related to NGAL were used to perform the search in the present meta-analysis. The search strategy at Embase database is reported in appendix 1.

2.4. Data extraction

The data were screened and summarized by two independent researchers. A checklist was used to summarize the data, including first author’s name, year of publication, number of patients, age, sex, number of UTI and non-UTI patients, urinary and serum levels of NGAL, and follow-up duration. In addition, mean and standard deviation of NGAL level, NGAL cut-offs, true positive (TP), false positive (FP), true negative (TN), false negative (FN), sensitivity, specificity and area under the curve of NGAL were also recorded. The checklist was designed according to the PRISMA guidelines (21). It should be noted that after summarizing the data, the two researchers’ checklists were compared and any disagreement was resolved by consulting a third researcher.

2.5. Quality control of articles

Risk of bias among included studies was assessed based on quality assessment of diagnostic accuracy studies (QUADAS-2) recommendations (22). Disagreement was resolved through discussion with a third researcher.

2.6. Statistical analysis

Analyses were performed using STATA 14.0 statistical software, applying the "midas" or "metan" commands. Analyses were stratified based on urinary and serum level of NGAL. At first, mean and standard deviation of urinary and serum levels of NGAL were compared between UTI and non-UTI groups. Finding was presented as standardized mean difference (SMD) with 95% confidence interval (95% CI). Publication bias was assessed using Egger’s test and presenting funnel plot. In the second part, we evaluated the discriminatory power of NGAL in identifying UTI in children and adolescents. For this purpose, the data were summarized as TP, FP, TN and FN. Findings were reported as area under the summary receiver operating characteristics (SROC) curve (AUC), sensitivity, specificity and diagnostic odds ratio with 95% CI. Publication bias was examined in this section using Deek’s funnel asymmetry test. In all analyses, heterogeneity was assessed using I² test.

3. Results

3.1. Study design

Database search eventually identified 485 articles. After eliminating duplicates and performing initial screening, 54 articles were studied in full. Of these, 42 articles were excluded.
Reasons for excluding the papers included non-UTI studies (n = 6), animal/in vitro studies (n = 5), lack of NGAL data (n = 2), duplicate reports (n = 2), absence of non-UTI group (n = 13), recurrent UTI (n = 1), adult studies (n = 4), and review articles (n = 7). Two conference papers that did not present our required data were excluded. Before excluding these two papers, we tried to obtain the required data using two strategies. First, we performed an extensive database search to find other published articles of the authors. Second, we sent two repetitive emails to corresponding authors. Finally, data from 12 studies were included in the present meta-analysis (11, 23-33) (Figure 1). There were 5 prospective cross-sectional studies, 2 retrospective cross-sectional studies, and 5 case-control studies. The sample size of included studies varied from 62 patients to 444 patients (total sample size of 2112 children, 50.9% male). 724 children had UTI and 1388 were non-UTI. The most common method of measuring NGAL was ELISA. Nine studies assessed urinary NGAL, 1 study was performed on serum level of NGAL and 2 studies examined both serum and urine NGAL levels. Tables 1 and 2 present the characteristics of included studies.

3.2. Risk of bias and publication bias
Quality control of the articles based on QUADAS-2 tools showed that the risk of bias in patient selection, flow and timing was high in 5 studies. This was due to the case-control nature of these studies. Sampling method was also retrospective in two studies. Therefore, the risk of bias in patient selection and flow and timing in these studies was unclear. In addition, the risk of bias and applicability of the index test was unclear in a study (Table 3, Figure 2). Finally, there was no evidence of publication bias in the present meta-analysis (Figure 2).

3.3. Meta-analysis
The mean difference of urinary and serum NGAL levels between the UTI and non-UTI patients
Figure 3 shows the mean difference of urinary and serum NGAL levels between UTI and non-UTI groups. As can be seen, both urinary levels (SMD = 1.11; 95% CI: 0.75 to 1.47; p <0.001; I^2 = 92.8; p <0.001) and serum levels (SMD = 0.84; 95% CI: 0.08 to 1.60; p = 0.031; I^2 = 89.8; p <0.001) of NGAL were significantly higher in UTI group compared to non-UTI group. As can be seen, there is high heterogeneity between studies. A subgroup analysis was performed to find the source of heterogeneity. We could not find the source of heterogeneity. Study design (p = 0.781), setting of patients (p = 0.147), sample size (p = 0.457), prevalence of UTI (p = 0.481) and NGAL assay method (p = 0.538) did not affect the SMD of urinary NGAL.

Diagnostic accuracy of urinary NGAL in detection of UTI
Data from three studies were included in the analyses of this section (11, 23-30, 32, 33). The AUC of urinary NGAL in diagnosis of UTI in children and adolescents was 0.90 (95% CI: 0.87 to 0.92) (Figure 4). Sensitivity and specificity of urinary NGAL in detecting UTI were 0.85 (95% CI: 0.77 to 0.90) and 0.81 (95% CI: 0.70 to 0.89), respectively (Figure 5). Additionally, diagnostic odds ratio of this urine biomarker was 23.78 (95% CI: 8.61 to 65.62).

Significant heterogeneity was also observed in this section (I^2 between 93.16 to 100%). A subgroup analysis based on NGAL cut-off point was performed to find the source of heterogeneity. As Table 4 shows, the cut-off points reported in the studies were divided into four groups of urinary NGAL level <20 ng / ml, 20-29.9 ng / ml, 30-39.9 ng / ml and 40 ng / ml and over. We observed optimum performance of urinary NGAL in cut-off points of 30 to 39.9 ng / ml. Analyses showed that AUC of urinary NGAL in detection of UTI was 0.95 (95% CI: 0.93 to 0.97) when the cut-off point was in the range of 30-39.9 ng / ml. The sensitivity, specificity and diagnostic odds ratio of NGAL at these cut-off points were 0.89 (95% CI: 0.64 to 0.97), 0.89 (95% CI: 0.71 to 0.97) and 67 (95% CI: 5 to 891), respectively.

Diagnostic accuracy of serum NGAL in detection of UTI
Data from three studies were included in the analyses of this section (26, 27, 31). The AUC of serum NGAL in diagnosis of UTI in children and adolescents was 0.83 (95% CI: 0.80 to 0.86) (Figure 4). Sensitivity and specificity of serum NGAL in detecting UTI were 0.85 (95% CI: 0.70 to 0.90) and 0.81 (95% CI: 0.69 to 0.88), respectively (Figure 6). Diagnostic odds ratio of this serum biomarker was 9.53 (95% CI: 1.52 to 59.65). Despite the obvious heterogeneity, subgroup analysis was not performed because the number of articles was small.

4. Discussion
The present meta-analysis showed that NGAL is able to detect UTI in children and adolescents. Stratified analysis showed that the urinary level of this biomarker had higher discriminatory power than its serum level and the optimum cut-off point was in the range of 30-39.9 ng / ml. When we assess the discriminatory precision of a test/biomarker, diagnostic odds ratio indicates the usefulness of the test/biomarker in the clinic. Urinary NGAL at cut-off points between 30-39.9 ng / ml had a diagnostic odds ratio of 67, which indicated its high applicability in diagnosis of UTI in children. In the present study, significant heterogeneity was observed among the studies. Unfortunately, the origin of this heterogeneity was not determined by subgroup analysis. The only factor that partially reduced the heterogeneity was the difference in cut-off points. It should be noted that the concept of heterogeneity has changed in recent years. In general, tests used for heterogeneity are low powered so that they may not be able to detect heterogene-
ity when the number of articles is small. On the other hand, the test may falsely show a heterogeneity when the number of included articles was high. For this reason, researchers have recently suggested that numerical values of heterogeneity should be reported as descriptive statistics and it should be interpreted intuitively from the clinical perspective (34).

The sensitivity and specificity reported in most studies included in the present meta-analysis were above 70%. Clinically, this level of sensitivity and specificity is divided into good and excellent groups, both of which represent good discriminatory performance of NGAL in diagnosis of UTI in children. Although the diversity of reported sensitivity and specificity between the studies was not clinically high, the $I^2$ test indicated high heterogeneity between eligible studies. Therefore, it seems that the heterogeneity reported in $I^2$ test has no clinically significant effect on the reported results. The aim of the present study was to evaluate the value of NGAL in the first episode of UTI in children and adolescents. Therefore, the diagnostic value of NGAL in recurrent UTI was excluded. The reason for these exclusion criteria was reducing heterogeneity between studies. The pattern of urinary NGAL levels in recurrent UTI appears to be different from the first episode of UTI. For example, in 2017, Forster et al. showed that urinary NGAL level in recurrent UTI patients was significantly lower than first episode UTI patients. These researchers suggest that a defect in urinary NGAL production may be a prerequisite for recurrent UTI (35). Of course, this is still a hypothesis and further studies are needed to reach a definite conclusion. Risk of bias regarding patient selection and flow and timing was high in 5 studies and unclear in 2 studies. This was due to the case-control design in 5 studies and retrospective sampling method in 2 other studies. However, since NGAL level was evaluated using a standard ELISA method, the applicability of the index test was rated as desirable in the present systematic review. One of the issues that should be considered when examining diagnostic performance of a biomarker is its cost-effectiveness. Although NGAL may improve the management of children with UTI, its economic impact should also be considered. To the best of our knowledge, there is no study on the cost-effectiveness of NGAL in diagnosis of UTI in children. But Shaw et al. in 2011 showed that NGAL is a cost-effective biomarker for diagnosis of acute kidney injury (36). In another study involving 10,000 patients, Parikh et al. showed that use of urinary NGAL plus serum creatinine in diagnosis of acute kidney injury not only improves patient management but also reduces treatment costs (37).

5. Conclusion

The present meta-analysis showed that urinary NGAL had a high diagnostic value in detection of UTI in children and adolescents with an optimum cut-off point in the range of 30-39.9 ng/ml.

6. Declarations

6.1. Acknowledgment

We are grateful to Dr. Nematollah Ataei, Dr. Mehdi Yaseri and Dr. Arash Sarveazad for their valuable helps.

6.2. Author contributions

- Study design: Mahmoud Yousefifard, Mostafa Hosseini
- Designing search strategy and performing the search: Mahmoud Yousefifard and Arash Abbasi
- Data gathering: Fardin Nabizadeh, Maryam Gardeh, Arash Abbasi
- Analysis and interpreting the result: Mahmoud Yousefifard, Mostafa Hosseini, Kosar Mohammad Ali
- Drafting the manuscript: Mahmoud Yousefifard, Kosar Mohammad Ali
- Critically revised the paper: All authors
- All authors approved the final version of manuscript and are accountable for all aspects of the work.

Authors ORCID
Arash Abbasi: 0000-0002-8859-2930
Fardin Nabizadeh: 0000-0002-4633-3340
Maryam Gardeh: 0000-0003-3487-5633
Kosar Mohammad Ali: 0000-0001-5533-2924
Mahmoud Yousefifard: 0000-0001-5181-4985
Mostafa Hosseini: 0000-0002-1334-246X

6.3. Funding

This study was funded and supported by Tehran University of Medical Sciences (TUMS); Grant no. 97-01-184-38231.

6.4. Conflict of interest

There is no conflict of interest.

References

1. Sastre JBL, Aparicio AR, Cotallo GDC, Colomer BE, Hernandez MC, de Hospitales Castrillo G. Urinary tract infection in the newborn: clinical and radio imaging studies. Pediatric Nephrology. 2007;22(10):1735-41.
2. Marild S, Jodal U. Incidence rate of first-time symptomatic urinary tract infection in children under 6 years of age. Acta Paediatrica. 1998;87(5):549-52.
3. Schappert S, Rechtsteiner E. Ambulatory medical care utilization estimates for 2007. Vital and Health Statistics Series 13, Data from the National Health Survey. 2011(169):1-38.
4. Mangiarotti P, Pizzini C, Fanos V. Antibiotic prophylaxis in children with relapsing urinary tract infections: review. Journal of chemotherapy. 2000;12(2):115-23.

5. DAS R, Ahmed T, Saha H, Shahrin L, Afroze F, SHAHID A, et al. Clinical risk factors, bacterial aetiology, and outcome of urinary tract infection in children hospitalized with diarrhoea in Bangladesh. Epidemiology & Infection. 2016;1-7.

6. Shaikh N, Matteo TK, Keren R, Ivanova A, Cui G, Moxey-Mims M, et al. Early antibiotic treatment for pediatric febrile urinary tract infection and renal scarring. JAMA pediatrics. 2016;170(9):848-54.

7. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595-610.

8. Jacobson SH, Eklof O, Eriksson CG, Lins L-E, Tidgren B, Winberg J. Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. Bmj. 1989;299(6701):703-6.

9. Izadi A, Yousefifard M, Nakhjavan-Shahraki B, Baikpour M, Mirzay Razaz J, Hosseini M. Diagnostic value of Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in detection of pediatric acute kidney injury; a systematic review and meta-analysis. International Journal of Pediatrics. 2016;4(11):3875-95.

10. Izadi A, Yousefifard M, Nakhjavan-Shahraki B, Baikpour M, Mirzay Razaz J, Ataei N, et al. Value of plasma/serum neutrophil gelatinase-associated lipocalin in detection of pediatric acute kidney injury; a systematic review and meta-analysis. International Journal of Pediatrics. 2016;4(11):3815-36.

11. Valdimarsson S, Jodal U, Barregard L, Hansson S. Urine neutrophil gelatinase-associated lipocalin and other biomarkers in infants with urinary tract infection and in febrile controls. Pediatric Nephrology. 2017;32(11):2079-87.

12. Lee H-E, Kim DK, Kang HK, Park K. The diagnosis of febrile urinary tract infection in children may be facilitated by urinary biomarkers. Pediatric Nephrology. 2015;30(1):123-30.

13. Kitao T, Kimata T, Yamanouchi S, Kato S, Tsuji S, Kaneko K. Urinary biomarkers for screening for renal scarring in children with febrile urinary tract infection: pilot study. The Journal of urology. 2015;194(3):766-71.

14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008-12.

15. Yousefifard M, Movaghar VR, Baikpour M, Ghelichkhani P, Hosseini M, Jafari AM, et al. Early versus Late Decompression for Traumatic Spinal Cord Injuries; a Systematic Review and Meta-analysis. Emergency. 2017;5(1):e37.

16. Yousefifard M, Baikpour M, Ghelichkhani P, Asady H, Nia KS, Jafari AM, et al. Screening Performance Characteristic of Ultrasonography and Radiography in Detection of Pleural Effusion; a Meta-Analysis. Emergency. 2016;4(1):1-10.

17. Ghelichkhani P, Yousefifard M, Nazemi L, Safari S, Hosseini M, Baikpour M, et al. The Value of Serum B-Subunit of Human Chorionic Gonadotropin Level in Prediction of Treatment Response to Methotrexate in Management of Ectopic Pregnancy; a Systematic Review and Meta-Analysis. International Journal of Pediatrics. 2016;4(9):3503-18.

18. Esrafilzadeh M, Yousefifard M, Hashemi H, Baratloo A, Forouzanfar MM, Rahmati F, et al. The value of serum creatine kinase in predicting the risk of rhabdomyolysis-induced acute kidney injury: a systematic review and meta-analysis. Clinical and experimental nephrology. 2016;20(2):153-61.

19. Safari S, Yousefifard M, Hashemi H, Baratloo A, Forouzanfar MM, Rahmati F, et al. The value of serum creatine kinase in predicting the risk of rhabdomyolysis-induced acute kidney injury: a systematic review and meta-analysis. Clinical and experimental nephrology. 2016;20(2):153-61.

20. Rahimi-Movaghar V, Yousefifard M, Ghelichkhani P, Baikpour M, Tafakhori A, Asady H, et al. Application of Ultrasonography and Radiography in Detection of Hemotherax: a Systematic Review and Meta-Analysis. EMERGENCY-An Academic Emergency Medicine Journal. 2016;4(3):116-26.

21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine. 2009;151(4):264-9.

22. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 2011;155(8):529-36.

23. Forster CS, Jackson E, Ma Q, Bennett M, Shah SS, Goldstein SL. Predictive ability of NGAL in identifying urinary tract infection in children with neurogenic bladders. Pediatric nephrology (Berlin, Germany). 2016;4(3):116-26.

24. Jarjes S, Chaturvedi S, Jose A, Sahni RD, Fleming JJ. Urinary Neutrophil Gelatinase Associated Lipocalin - A Sensitive Marker for Urinary Tract Infection in Children. Indian journal of nephrology. 2016;33(8):1365-74.

25. Jung N, Byun HJ, Park JH, Kim JS, Kim HW, Ha JY. Diagnostic accuracy of urinary biomarkers in infants younger than 3 months with urinary tract infection. Korean jour-
26. Kim BH, Yu N, Kim HR, Yun KW, Lim IS, Kim TH, et al. Evaluation of the optimal neutrophil gelatinase-associated lipocalin value as a screening biomarker for urinary tract infections in children. Annals of laboratory medicine. 2014;34(5):354-9.
27. Krzemien G, Panczyk-Tomaszewksa M, Adamczuk D, Kotula I, Demkow U, Szmigielska A. Neutrophil Gelatinase-Associated Lipocalin: A Biomarker for Early Diagnosis of Urinary Tract Infections in Infants. Advances in experimental medicine and biology. 2018;1047:71-80.
28. Lubell TR, Barasch JM, Xu K, Ieni M, Cabrera KL, Dayan PS. Urinary Neutrophil Gelatinase-Associated Lipocalin for the Diagnosis of Urinary Tract Infections. Pediatrics. 2017;140(6):e20171090.
29. Nickavar A, Safaeian B, Valavi E, Moradpour F. Validity of Neutrophil Gelatinase Associated Lipocaline as a Biomarker for Diagnosis of Children with Acute Pyelonephritis. Urology journal. 2016;13(5):2860-3.
30. Safdar OY, Shalaby MA, Toffaha WM, Turki AA, Toffa WM, Ghunaim AH, et al. Neutrophil gelatinase-associated lipocalin as an early marker for the diagnosis of urinary tract infections in Saudi children. Journal of Nephrology & Therapeutics. 2015;5(6):1-4.
31. Seo WH, Nam SW, Lee EH, Je BK, Yim HE, Choi BM. A rapid plasma neutrophil gelatinase-associated lipocalin assay for diagnosis of acute pyelonephritis in infants with acute febrile urinary tract infections: a preliminary study. European journal of pediatrics. 2014;173(2):229-32.
32. Yilmaz A, Sevketoglu E, Gedikbasi A, Karyagar S, Kiyak A, Mulazimoglu M, et al. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatric nephrology (Berlin, Germany). 2009;24(12):2387-92.
33. Yim HE, Yim H, Bae ES, Woo SU, Yoo KH. Predictive value of urinary and serum biomarkers in young children with febrile urinary tract infections. Pediatric nephrology (Berlin, Germany). 2014;29(11):2181-9.
34. Lin L. Comparison of four heterogeneity measures for meta-analysis. Journal of Evaluation in Clinical Practice. 2020;26(1):376-84.
35. Forster CS, Johnson K, Patel V, Wax R, Rodig N, Barasch J, et al. Urinary NGAL deficiency in recurrent urinary tract infections. Pediatric nephrology (Berlin, Germany). 2017;32(6):1077-80.
36. Shaw AD, Chalfin DB, Kleintjens J. The economic impact and cost-effectiveness of urinary neutrophil gelatinase-associated lipocalin after cardiac surgery. Clinical therapeutics. 2011;33(11):1713-25.
37. Parikh A, Rizzo JA, Canetta P, Forster C, Sise M, Maarouf O, et al. Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis. PLoS One. 2017;12(5):e0178091.
| Author; year; country | Study type | Setting | Age | Sample size | No. of boys | Number of patients UTI / Non UTI | UTI group | Control group | NGAL assay methods | Source of NGAL |
|------------------------|------------|---------|-----|-------------|-------------|---------------------------------|-----------|---------------|------------------|----------------|
| Forster; 2018; USA     | PCS        | Neurogenic bladder | <18 | 201         | 102         | 24 / 177                        | UTI       | No UTI        | ELISA            | Urine          |
| Jagadesan; 2019; India | PCS        | Suspected UTI      | 0.2 to 5 years | 100         | 43          | 34 / 66                         | UTI       | No UTI        | Turbidometric immunoassay | Urine          |
| Jung; 2018; Korea      | RCS        | Suspected UTI      | <3 month | 422         | 267         | 102 / 320                       | UTI       | No UTI        | Microparticle immunoassay | Urine          |
| Kim; 2014; Korea       | RCS        | Suspected UTI      | 3.87±2.59 years | 444         | 177         | 107 / 337                       | UTI       | No UTI        | ELISA            | Urine/Serum    |
| Kremien; 2017; Poland  | PCS        | Suspected UTI      | 1 to 12 months | 84          | 42          | 66 / 18                         | Febrile and non-febrile UTI | No UTI | ELISA        | Urine/Serum    |
| Lubell; 2017; USA      | PCS        | Suspected UTI      | 0 to 2 years | 260         | 118         | 35 / 225                        | Febrile UTI | Non-UTI | ELISA        | Urine          |
| Nickavar; 2016; Iran   | CCS        | UTI and non-UTI    | 0 to 12 years | 63          | 23          | 37 / 26                         | UTI       | Healthy control | ELISA            | Urine          |
| Safdar; 2015; Saudi Arabia | PCS    | Suspected UTI      | 0 to 14 years | 73          | 33          | 31 / 42                         | UTI       | Non-UTI       | NR               | Urine          |
| Seo; 2013; Korea       | CCS        | UTI and non-UTI    | 0-1 years | 62          | 40          | 47 / 15                         | UTI       | Healthy control | ELISA            | Serum          |
| Valdimarsson; 2017; Sweden | CCS  | UTI and non-UTI    | 0-1 years | 185         | 105         | 108 / 77                        | UTI       | Healthy control | ELISA            | Urine          |
| Yilmaz; 2009; Turkey   | CCS        | UTI and non-UTI    | 0.1 to 14 years | 89          | 24          | 60 / 29                         | UTI       | Healthy control | ELISA            | Urine          |
| Yim; 2014; Korea       | CCS        | UTI and non-UTI    | Mean 23 months | 129         | 84          | 73 / 56                         | UTI       | Healthy control | Immunosorbent assay | Urine          |

CCS: Case-Control study; ELISA: enzyme-linked immunosorbent assay; NGAL: neutrophil gelatinase-associated lipocalin; PCS: Prospective cross-sectional study; RCS: Cross-sectional study; UTI: Urinary tract infection.
### Table 2: Characteristics of included studies in assessment of diagnostic accuracy of NGAL in detection of urinary tract infection

| Author; year; country | Sample size | No. of boys | Number of patients UTI / Non UTI | UTI group | Control group | Source of NGAL | Cut-off ng/ml | TP | FP | FN | TN |
|-----------------------|-------------|-------------|---------------------------------|-----------|---------------|----------------|---------------|----|----|----|----|
| Forster; 2018, USA    | 201         | 102         | 24 / 100                        | UTI       | No UTI        | Urine          | 229           | 20 | 14 | 4  | 86 |
| Jagadesan; 2019, India| 100         | 43          | 34 / 66                         | UTI       | No UTI        | Urine          | 27            | 27 | 21 | 7  | 45 |
| Jung; 2018, Korea     | 422         | 267         | 102 / 320                       | UTI       | No UTI        | Urine          | 46.2          | 92 | 24 | 10 | 296|
| Kim; 2014, Korea      | 444         | 177         | 107 / 337                       | UTI       | No UTI        | Urine          | 5.75          | 199| 134| 306| 151|
| Krzemien; 2017, Poland| 84          | 42          | 42 / 18                         | Febrile UTI | No UTI        | Urine          | 42.2          | 31 | 5  | 11 | 13 |
|                       |             |             |                                 | Febrile UTI  | No UTI        | Serum          | 76.2          | 39 | 1  | 3  | 17 |
|                       |             |             |                                 | Non-Febrile UTI | No UTI        | Serum          | 39            | 20 | 8  | 4  | 10 |
| Lubell; 2017, USA     | 260         | 118         | 35 / 225                        | Febrile UTI | Non-UTI       | Urine          | 39.1          | 34 | 10 | 1  | 215|
| Nickavar; 2016, Iran  | 63          | 23          | 37 / 26                         | UTI       | Healthy control | Urine          | 0.2           | 28 | 6  | 9  | 20 |
| Safdar; 2015, Saudi Arabia | 73     | 33          | 31 / 42                         | UTI       | Non-UTI       | Urine          | 35.83         | 25 | 10 | 17 | 21 |
| Seo; 2013, Korea      | 62          | 40          | 47 / 15                         | UTI       | Healthy control | Serum          | 61            | 35 | 3  | 12 | 12 |
| Valdimarsson; 2017, Sweden | 185    | 105         | 108 / 77                        | UTI       | Healthy control | Urine          | 38            | 100| 1  | 8  | 12 |
| Yilmaz; 2009, Turkey  | 89          | 24          | 60 / 29                         | UTI       | Healthy control | Urine          | 20            | 58 | 7  | 2  | 22 |
| Yim; 2014, Korea      | 129         | 84          | 73 / 56                         | UTI       | Healthy control | Urine          | 23.95         | 60 | 9  | 13 | 47 |

FN: False Negative; FP: False positive; NGAL: neutrophil gelatinase-associated lipocalin; UTI: Urinary tract infection; TN: True negative; TP: True positive.

### Table 3: Risk of bias assessment among included studies

| Author; year | Patient selection | Index test | Reference standard | Flow and timing | Applicability |
|--------------|-------------------|------------|--------------------|-----------------|---------------|
| Forster; 2018| ©                 | ©          | ©                  | ©               | ©             |
| Jagadesan; 2019| ©              | ©          | ©                  | ©               | ©             |
| Jung; 2018   | ©                 | ©          | ©                  | ©               | ©             |
| Kim; 2014    | §                 | ©          | ©                  | ©               | ©             |
| Krzemien; 2017| ©                | ©          | ©                  | ©               | ©             |
| Lubell; 2017 | ©                 | ©          | ©                  | ©               | ©             |
| Nickavar; 2016| ©              | ©          | ©                  | ©               | ©             |
| Safdar; 2015 | ©                 | ©          | ©                  | ©               | ©             |
| Seo; 2013    | ©                 | ©          | ©                  | ©               | ©             |
| Valdimarsson; 2017, Sweden | © | © | © | © | © |
| Yilmaz; 2009 | ©                 | ©          | ©                  | ©               | ©             |
| Yim; 2014    | ©                 | ©          | ©                  | ©               | ©             |

©: Low risk of bias, §: High risk of bias, ©: Unclear Risk

### Table 4: Diagnostic performance of NGAL in detection of UTI at different cut-offs

| Cut offs | AUC | Sensitivity | Specificity | Positive LR | Negative LR | Odds ratio |
|----------|-----|-------------|-------------|-------------|-------------|------------|
| <20 ng/ml| 0.73 (0.69 to 0.77) | 0.73 (0.63 to 0.80) | 0.58 (0.32 to 0.80) | 1.7 (0.9 to 3.4) | 0.47 (0.25 to 0.89) | 4 (1 to 14) |
| 20–29.9 ng/ml | 0.85 (0.81 to 0.88) | 0.88 (0.74 to 0.95) | 0.76 (0.66 to 0.84) | 3.7 (2.5 to 5.4) | 0.16 (0.07 to 0.36) | 23 (8 to 67) |
| 30–39.9 ng/ml | 0.95 (0.93 to 0.97) | 0.89 (0.64 to 0.97) | 0.89 (0.71 to 0.97) | 8.3 (2.4 to 28.7) | 0.12 (0.03 to 0.53) | 67 (5 to 891) |
| >40 ng/ml | 0.92 (0.89 to 0.94) | 0.84 (0.72 to 0.91) | 0.87 (0.79 to 0.93) | 6.4 (3.2 to 12.8) | 0.19 (0.10 to 0.35) | 34 (10 to 117) |

AUC: area under the curve; LR: likelihood ratio.
Figure 1: PRISMA flow diagram for the selection process
Figure 2: Risk of bias and publication bias among eligible studies. Risk of bias regarding patient selection and flow and timing was high in 5 studies and unclear in 2 studies. Risk of bias and applicability of index test was unclear in 1 study. There was no evidence of publication bias in standardized mean difference ($P_{Egger's test} = 0.286$) and discriminatory accuracy ($P_{Deek's test} = 0.140$) assessment of neutrophil gelatinase-associated lipocalin in detection of urinary tract infection.
Figure 3: Standardized mean difference (SMD) of neutrophil gelatinase-associated lipocalin (NGAL) between urinary tract infected (UTI) and non-UTI children. Urine and serum levels of NGAL were significantly higher in UTI children. CI: Confidence interval.

| Author     | Year | SMD (95% CI)       |
|------------|------|--------------------|
| **Urine**  |      |                    |
| Forster    | 2018 | 2.32 (1.79, 2.85)  |
| Forster    | 2018 | 1.16 (0.84, 1.48)  |
| Jagadesan  | 2019 | 0.89 (0.46, 1.32)  |
| Jung       | 2018 | 0.84 (0.61, 1.07)  |
| Kim        | 2014 | 0.12 (-0.02, 0.27) |
| Krzemien   | 2017 | 0.87 (0.29, 1.44)  |
| Krzemien   | 2017 | 0.27 (-0.35, 0.88) |
| Lubell     | 2017 | 1.62 (1.24, 2.00)  |
| Nickavar   | 2016 | 0.74 (0.22, 1.25)  |
| Safdar     | 2015 | 0.93 (0.44, 1.42)  |
| Valdimarsson | 2017 | 1.14 (0.55, 1.74)  |
| Valdimarsson | 2017 | 1.34 (1.00, 1.68)  |
| Yilmaz     | 2009 | 2.28 (1.73, 2.84)  |
| Yim        | 2014 | 1.09 (0.71, 1.46)  |
| **Subtotal** | **I-squared = 92.8%, p = 0.000** | **1.11 (0.75, 1.47)** |
| **Serum**  |      |                    |
| Kim        | 2014 | 0.19 (-0.00, 0.38) |
| Krzemien   | 2017 | 2.07 (1.40, 2.74)  |
| Krzemien   | 2017 | 0.68 (0.05, 1.31)  |
| Seo        | 2013 | 0.55 (-0.04, 1.14) |
| **Subtotal** | **I-squared = 89.8%, p = 0.000** | **0.84 (0.08, 1.60)** |
| **Overall** | **I-squared = 92.5%, p = 0.000** | **1.05 (0.74, 1.36)** |

NOTE: Weights are from random effects analysis.
Figure 4: Area under the summary receiver operating characteristics (SROC) curve (AUC) of urine and serum neutrophil gelatinase-associated lipocalin (NGAL) in detection of urinary tract infection. CI: Confidence interval.
Figure 5: Sensitivity, specificity, diagnostic score and diagnostic odds ratio of urine neutrophil gelatinase-associated lipocalin (NGAL) in detection of urinary tract infection. CI: Confidence interval.

This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: http://journals.sbmu.ac.ir/aaem
Figure 6: Sensitivity, specificity, diagnostic score and diagnostic odds ratio of serum neutrophil gelatinase-associated lipocalin (NGAL) in detection of urinary tract infection. CI: Confidence interval.